EJErik Jakobsen

Erik Jakobsen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Erik Jakobsen has a total of 460 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Disparities in initiating standard first-line cancer treatment and survival for patients with an immigrant background: a Danish register-based cohort study

    by Emma N. Ishøy, Maria Kristiansen, Ismail Gögenur, Erik Jakobsen, Lars Lund, Fie Stegenborg, Susanne Rosthøj, Mia K. Grand, Pernille Bidstrup, Morten Sodemann, et al.

    Background and purpose: Individuals with an immigrant background may face barriers to healthcare. However, evidence on differences in cancer treatment and survival between patients with an immigrant background and patients of Danish origin is limited. Patients and methods: We included patients aged ≥50 years diagnosed with a first primary colon, lung, prostate, or kidney cancer between 2011 and 2022 from national clinical cancer databases. First-line treatment initiation (30/90 days) and survival (1/5 years) were assessed using risk ratios (RRs) comparing patients with an immigrant background to those of Danish origin. Immigrant backgrounds were categorized according to their origin in (1) other Western countries, (2) Central and Eastern Europe, and (3) the Middle East, North Africa, and Central Asia.Results: Overall, there were no systematic differences in the initiation of first-line treatment or survival between patients with an immigrant background and patients of Danish origin. Exceptions included lower probability of initiating treatment (30-day RR: 0.76 [95% confidence interval (CI): 0.62; 0.93] and 90-day RR: 0.92 [95% CI: 0.87; 0.98]) and 1-year risk of death (RR: 0.85 [95% CI: 0.77; 0.93]) among lung cancer patients from Central and Eastern Europe, lower 30-day treatment initiation among patients from the Middle East, North Africa, and Central Asia (RR: 0.80 [95% CI: 0.64; 1.00]), and higher 5-year risk of death among prostate cancer patients from other Western countries (RR: 1.16 [95% CI: 1.01; 1.34]).Interpretation: Overall, patients with an immigrant background had similar initiation of first-line cancer treatment and survival to those of Danish origin, with some statistically significant differences but no consistent pattern across cancer types or regions of origin.

  • Prevalence of concurrent severe self-reported late symptoms and functional limitations in cancer survivors: a cross-sectional study of sociodemographic, clinical, and lifestyle associations

    by Trille Kristina Kjaer, Anne Katrine Graudal Levinsen, Erik Jakobsen, Ismail Gögenur, Michael Borre, Peer Christiansen, Robert Zachariae, Peter Christensen, Peter de Nully Brown, Lisbet Rosenkrantz Hölmich, et al.

    This population-based study investigated the prevalence of concurrent severe symptoms and functional limitations among Danish cancer survivors, examining associations with sociodemographic, clinical, and lifestyle factors. We conducted a cross-sectional analysis using data from the nationwide SEQUEL questionnaire study (2022), including 40,766 survivors 2- to 12-year post-diagnosis (2010-2019). Up to 21 symptoms, five functioning domains, and sexual satisfaction were assessed using validated instruments (EORTC QLQ-C30, EORTC Item Library, QLQ-SHQ22, GAD-7, PHQ-9). Data were obtained from Danish registries, clinical databases, and self-report. Symptoms and functional limitations were categorized as severe using predefined thresholds. Ordinal logistic regression models examined factors associated with concurrent symptoms. Mean symptom count was 4.1 for women (range 0-21, SD 3.19) and 3.3 for men (range 0-20, SD 2.72), with 25% of women and 16% of men experiencing ≥ 5 concurrent severe symptoms. Lung cancer survivors reported the highest symptom burden. Factors significantly associated with concurrent symptoms included short education, lower income, living alone, multiple comorbidities (CCI ≥ 2), advanced disease, palliative treatment, current smoking, and higher BMI, with ORs ranging from 1.29-2.19 (women) and 1.23-2.25 (men). Impaired functioning showed similar associations. Concurrent late symptoms are common among cancer survivors, indicating complex health issues varying by cancer type and clinical characteristics, with clear socioeconomic disparities and lifestyle associations. These findings highlight subgroups who may benefit from interventions targeting multiple symptoms and underscore the importance of addressing social determinants and lifestyle factors in survivorship care.


  • Open Access

    Capecitabine monotherapy as first-line treatment in advanced HER2-normal breast cancer – a nationwide, retrospective study

    by Alan Celik, Tobias Berg, Magnus Gibson, Maj-Britt Jensen, Iben Kümler, Saskia Eßer-Naumann, Erik H. Jakobsen, Ann Knoop, Dorte Nielsen

    Background and purpose: Capecitabine can be used as first-line treatment for advanced breast cancer. However, real-world data on efficacy of capecitabine in this setting is sparse. The purpose of the study is to evaluate outcomes of patients with Human Epidermal Growth Factor Receptor (HER2)-normal advanced breast cancer treated with capecitabine monotherapy as first-line treatment. Material and Methods: The study utilized the Danish Breast Cancer Group (DBCG) database and was conducted retrospectively across all Danish oncology departments. Inclusion criteria were female patients, with HER2-normal advanced breast cancer treated with capecitabine monotherapy as the first-line treatment from 2010 to 2020. The primary endpoints were overall survival (OS) and progression-free survival (PFS). Results: A total of 494 patients were included. Median OS was 16.4 months (95% confidence interval [CI]: 14.5–18.0), and median PFS was 6.0 months (95% CI: 5.3–6.7). Patients with estrogen receptor (ER)-positive disease had significantly longer OS (median: 22.8 vs. 10.5 months, p < 0.001) and PFS (median: 7.4 vs. 4.9 months, p = 0.003), when compared to ER-negative patients. Stratifying by age, patients under 45 years displayed a median PFS of 4.1 months, while those aged 45–70 years and over 70 years had median PFS of 5.7 and 7.2 months, respectively (p = 0.01). Interpretation: In this nationwide study, the efficacy of capecitabine as a first-line treatment for HER2-normal advanced breast cancer is consistent with other, mainly retrospective, studies. However, when assessed against contemporary and newer treatments, its effectiveness appears inferior to alternative chemotherapies or targeted therapies.

  • Open Access

    Forecasting lung cancer incidence, mortality, and prevalence to year 2030

    by Erik Jakobsen, Karen Ege Olsen, Mette Bliddal, Malene Hornbak, Gitte F. Persson, Anders Green

    Background: Lung cancer incidence and prevalence is increasing worldwide and there is a focus on prevention, early detection, and development of new treatments which will impact the epidemiological patterns of lung cancer. The clinical characteristics and the trends in incidence, mortality, and prevalence of lung cancer in Denmark from 2006 through 2015 are described and a model for predicting the future epidemiological profile of lung cancer through 2030 is introduced. Methods: The study population comprised all cases of lung cancer, registered in the Danish Cancer Registry, who were alive on January 1, 2006 or had a first-time ever diagnosis of lung cancer during 2006 through 2015. Information on morphology, stage of the disease, comorbidity and survival was obtained from other Danish health registers. Based on NORDCAN data and estimated patient mortality rates as well as prevalence proportions for the period 2006 through 2015, future case numbers of annual incidence, deaths, and resulting prevalence were projected. Results: A total of 44.291 patients were included in the study. A shift towards more patients diagnosed with lower stages and with adenocarcinoma was observed. The incidence increased and the patient mortality rate decreased significantly, with a doubling of the prevalence during the observation period. We project that the numbers of prevalent cases of lung cancer in Denmark most likely will increase from about 10,000 at the end of 2015 to about 23,000 at the end of 2030. Conclusions: Our findings support that lung cancer is being diagnosed at an earlier stage, that incidence will stop increasing, that mortality will decrease further, and that the prevalence will continue to increase substantially. Projections of cancer incidence, mortality, and prevalence are important for planning health services and should be updated at regular intervals.


  • Open Access

    Forecasting lung cancer incidence, mortality, and prevalence to year 2030

    by Erik Jakobsen, Karen Ege Olsen, Mette Bliddal, Malene Hornbak, Gitte S Persson, Anders Green

    Background Lung cancer incidence and prevalence is increasing worldwide and there is a focus on prevention, early detection, and development of new treatments which will impact the epidemiological patterns of lung cancer. The clinical characteristics and the trends in incidence, mortality, and prevalence of lung cancer in Denmark from 2006 through 2015 is described and a model for predicting the future epidemiological profile of lung cancer through 2030 is introduced.Methods The study population comprised all cases of lung cancer, registered in the Danish Cancer Registry, who were alive on January 1, 2006 or had a first-time ever diagnosis of lung cancer during 2006 through 2015. Information on morphology, stage of the disease, comorbidity and survival was obtained from other Danish health registers. Based on NORDCAN data and estimated patient mortality rates as well as prevalence proportions for the period 2006 through 2015, future case numbers of annual incidence, deaths, and resulting prevalence were projected.Results A total of 44.291 patients were included in the study. A shift towards more patients diagnosed with lower stages and with adenocarcinoma was observed. The incidence increased and the patient mortality rate decreased significantly, with a doubling of the prevalence during the observation period. We project that the numbers of prevalent cases of lung cancer in Denmark most likely will increase from about 10,000 at the end of 2015 to about 23,000 at the end of 2030.Conclusions Our findings support that lung cancer is being diagnosed at an earlier stage, that incidence will stop increasing, that mortality will decrease further, and that the prevalence will continue to increase substantially. Projections of cancer incidence, mortality, and prevalence are important for planning health services and should be updated at regular intervals.

    • 1 August 2020
      • Vol. 67  (8)

    Agreement between the Danish Cancer Registry and the Danish Lung Cancer Registry

    by Jane Christensen, Anne Mette Tranberg Kejs, Lise Kristine Hojsgaard Schmidt, Jes Sogaard, Margit Caroline Rasted, Ole Andersen, Erik Jakobsen

    Introduction: The Danish Cancer Registry (DCR) and the Danish Lung Cancer Registry (DLCR) are nation-wide registries recording Danish patients with lung cancer (LC). The aim of this study was to assess data agreement and possible consequences hereof on estimation of survival between patients in the two registries. Methods: Descriptive statistics were used for comparison of registered patients in 2013-2014 in the DCR and the DLCR. Furthermore, the one-year relative survival (1y-RS) and Cox proportional mortality hazard rates (MRR) were calculated. Results: In 2013-2014, a total of 9,111 Danish residents were identified with LC in the DCR and 9,316 were found in the DLCR. Merging the two registries showed an agreement of 87%, whereas 6% were included only in the DCR and 8% only in the DLCR. Including patients only registered in one registry, but who seemed to meet the inclusion criteria of both registries, would increase the agreement to 95%. No differences were seen for 1y-RS. However, MRR for patients in the DLCR was significantly lower than for patients in the DCR: 0.94 (95% confidence interval: 0.91-0.98). Conclusions: Surprisingly, the DCR registered fewer patients in 2013-2014 than the DLCR, even though they employ the same primary data source. The agreement between the DCR and the DLCR was 87%; this may be increased to 95% if patients who seemed to meet the inclusion criteria of the other register were also included. The discrepancies found were mainly due to different definitions of dates of diagnosis, registrations probably missed by the algorithms and possible registration errors. Discrepancies resulted in a significant difference in MRR, but not in 1y-RS.


  • P1.12-13 The Past, Present, and Future of SCLC and NSCLC Incidence, Mortality, and Prevalence in Denmark During 2006 Through 2030

    by A. Green, K. Olsen, G. Persson, M. Bliddal, M. Hornbak, H. Christensen, E. Jakobsen

  • Impact of health care organization on surgical lung cancer care

    by D.J. Heineman, F. Hoeijmakers, N. Beck, C. Dickhoff, J.M. Daniels, W.H. Schreurs, E. Jakobsen


  • Open Access

    Treatment, no treatment and early death in Danish stage I lung cancer patients

    by Niels Lyhne Christensen, Susanne Dalton, Jesper Ravn, Jane Christensen, Erik Jakobsen, Torben Riis Rasmussen


  • Treatment patterns and long-term survival for unresected stage III non-small cell lung cancer patients: A nationwide register study in Denmark

    by A. Green, K.E. Olsen, M. Bliddal, H.N. Christensen, E. Jakobsen

    Background: Patients with stage III non-small cell lung cancer (NSCLC) is a heterogeneous population with resectable or unresectable tumors. Current standard of care for unresectable disease has since long been either curatively intended chemoradiotherapy (CRT) followed by active surveillance, or palliative treatment for CRT ineligible patients. Recently, published data have shown survival benefit of CRT followed by immunotherapy (durvalumab). The aim was to investigate long-term survival, treatment patterns, and characteristics for unresected stage III NSCLC patients in a real-life setting.